![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1272775
¼¼°èÀÇ Åå¼ÒÀÌµå ¹é½Å ½ÃÀå(2023-2030³â)Global Toxoid Vaccine Market - 2023-2030 |
¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº 2022³â 55¾ï 8,560¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â ÃÖ´ë 82¾ï 6,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. ÀÌ ½ÃÀåÀº ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 5.1%ÀÇ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Åå¼ÒÀÌµå ¹é½Å ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç´Â ÀÌ Áö¿ªÀÇ ³ôÀº CAGR ¼ºÀå·üÀ» º¸ÀåÇÕ´Ï´Ù.
¿¹¸¦ µé¾î, 2022³â 10¿ù ÀεµÀÇ ÁÖ¿ä »ý¸í°øÇÐ ±â¾÷ Áß ÇϳªÀÎ ÆÄ³ª¼¼¾Æ ¹ÙÀÌ¿ÀÅØ(Panacea Biotec)Àº WHO°¡ »çÀü ÀÎÁõÇÑ ¿ÏÀü ¾×»ó 5°¡ ¹é½Å Easyfive-TT(DTwP-HepB-Hib) °ø±ÞÀ» À§ÇØ À¯´Ï¼¼ÇÁ(UNICEF)¿Í ¹ü¹Ìº¸°Ç±â±¸(PAHO) À¸·ÎºÎÅÍ 1¾ï 2,730¸¸ ´Þ·¯(ÇÑÈ ¾à 1,040¾ï ¿ø) »ó´çÀÇ Àå±â °ø±Þ °è¾àÀ» ü°áÇß½À´Ï´Ù.
¶ÇÇÑ 2022³â 9¿ù¿¡´Â ÄÚºñµå ¹é½ÅÀÇ ¼º°ø¿¡ ÈûÀÔ¾î Àεµ Ç÷û¿¬±¸¼Ò°¡ µðÇÁÅ׸®¾Æ, ¹éÀÏÇØ, ÆÄ»ódz(Tdap) ¹é½Å ¼³°è¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ÀÌ È¸»ç´Â Àεµ ÀǾàǰ °ü¸®±¹(DCGI)ÀÇ Àü¹®°¡ ÆÐ³Î¿¡ 2-3»ó ÀÓ»ó½ÃÇè µ¥ÀÌÅ͸¦ Á¦ÃâÇÏ°í ¹é½Å Á¦Á¶ Çã°¡¸¦ ¿äûÇß½À´Ï´Ù. ÀÌó·³ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Åå¼ÒÀÌµå ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº ÆÄ»ódz°ú °°Àº ƯÁ¤ ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» ÀÏÀ¸Å°±â À§ÇØ Åå¼ÒÀ̵带 Ç׿øÀ¸·Î »ç¿ëÇÏ´Â ¹é½Å ½ÃÀåÀÔ´Ï´Ù. ÀÌ À¯ÇüÀÇ ¹é½ÅÀº ¼ºÀΰú 7¼¼ ÀÌ»ó ¾î¸°ÀÌÀÇ ÆÄ»ódz ¿¹¹æ¿¡ ƯÈ÷ È¿°úÀûÀÔ´Ï´Ù.
Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº °¨¿°¼º ÁúȯÀÇ À¯Çà, ¹é½Å Á¢Á¾ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ ÃßÁøÀ» À§ÇÑ Á¤ºÎ ÁÖµµÀÇ ³ë·Â µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ½ÃÀå ÁÖ¿ä ¾÷üµéÀÇ Áö¼ÓÀûÀÎ R&D Ȱµ¿°ú ½ÅÁ¦Ç° Ãâ½Ã´Â ¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ðÀÚ ¹× ½Å»ý¾Æ ÆÄ»ódz ÅðÄ¡(MNTE) ÀÌ´Ï¼ÅÆ¼ºê¿Í °°Àº µ¶¼Ò ¹é½Å¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀº ¼¼°è µ¶¼Ò ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »ê¸ð ¹× ½Å»ý¾Æ ÆÄ»ódz(MNT)Àº ºÒ°áÇÑ ºÐ¸¸°ú ÅÈÁÙ °ü¸®·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ´Â »ý¸íÀ» À§ÇùÇÏ´Â Áúº´À¸·Î, MNTE ÀÌ´Ï¼ÅÆ¼ºê´Â MNT ¹ßº´·üÀ» ³·Ãç ´õ ÀÌ»ó °øÁß º¸°Ç¿¡ Å« ¹®Á¦°¡ µÇÁö ¾Ê´Â ¼öÁØÀ¸·Î ³·Ãß´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.
°¢±¹ Á¤ºÎ¿Í ¼¼°èº¸°Ç±â±¸(WHO)¿Í °°Àº ±¹Á¦±â±¸´Â ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥°ú °øÁߺ¸°Ç Ä·ÆäÀο¡ ÀÚ±ÝÀ» Áö¿øÇϰí MNTE ÀÌ´Ï¼ÅÆ¼ºê¸¦ Àû±ØÀûÀ¸·Î Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀÇ °á°ú·Î ¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÆÄ»ódz Åå¼ÒÀÌµå ¹é½ÅÀº ÁÖ»ç ºÎÀ§ÀÇ ÅëÁõ, ¹ßÀû µî ±¹¼Ò ¹ÝÀÀ°ú ¹ß¿, ÇÇ·Î, ±ÙÀ°Åë µî Àü½Å ¹ÝÀÀÀÇ ¹ß»ýÀ¸·Î ÀÎÇØ »ç¿ëÀÌ Á¦Çѵ˴ϴÙ. ¹é½Å¿¡ ´ëÇÑ ½É°¢ÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀº µå¹°Áö¸¸ ±ØÈ÷ ÀϺο¡¼ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ ¹é½Å Á¢Á¾ÀÇ º¸±ÞÀ¸·Î ÆÄ»ódz ¹ßº´·üÀÌ ÇöÀúÈ÷ °¨¼ÒÇϰí ÀÖÀ¸¸ç, ÀÌ¿¡ µû¶ó ¹é½Å ¼ö¿äµµ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ÆÄ»ódz Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº °è¾à ½ÃÀåÀÌ Å« ºñÁßÀ» Â÷ÁöÇÏ´Â °è¾à ½ÃÀå°ú ¹Î°£ ½ÃÀåÀ¸·Î ¾çºÐȵǾî ÀÖ½À´Ï´Ù.
Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº Àü¿°º´À¸·Î ÀÎÇØ ´Ù¼Ò º¹ÀâÇÑ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÆÄ»ódz Åå¼ÒÀÌµå ¹é½ÅÀº Á¤±â ¿¹¹æÁ¢Á¾¿¡ Æ÷ÇԵǾî Àֱ⠶§¹®¿¡ ¼ö¿ä°¡ ¾ÈÁ¤ÀûÀÌÁö¸¸, µðÇÁÅ׸®¾Æ Åå¼ÒÀÌµå ¹é½ÅÀº ¼¼°è ¸¹Àº Áö¿ª¿¡¼ µðÇÁÅ׸®¾Æ ¹ß»ý·üÀÌ °¨¼ÒÇÔ¿¡ µû¶ó ¼ö¿ä°¡ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ »óȲ¿¡µµ ºÒ±¸ÇÏ°í ¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº °¨¿°º´À» °ü¸®Çϱâ À§ÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ÀÇ Çʿ伺ÀÌ Áö¼ÓµÇ°í Àֱ⠶§¹®¿¡ ¾ÈÁ¤ÀûÀÎ ¼ºÀå¼¼¸¦ À̾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÆÒµ¥¹ÍÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â Àü¹ÝÀûÀÎ ¿µÇâÀº Áß°£ Á¤µµ¿¡ ±×Ä¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼¼°è Åå¼ÒÀÌµå ¹é½Å ½ÃÀåÀº ·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ªÀÇ ºÐÀïÀ¸·Î ÀÎÇØ Å« ¿µÇâÀ» ¹ÞÁö ¾Ê°í ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ »ý»ê°ú À¯ÅëÀÌ ºÐÀï Áö¿ª ¿ÜºÎ¿¡ À§Ä¡ÇØ Àֱ⠶§¹®ÀÔ´Ï´Ù. ±×·¯³ª ÀÌ Áö¿ªÀÇ ºÐÀïÀ¸·Î ÀÎÇØ °ø±Þ¸ÁÀÌ ²÷°Ü ¹é½ÅÀ» Æ÷ÇÔÇÑ ÀÇ·á¿ëǰ¿¡ ´ëÇÑ Á¢±ÙÀÌ ¾î·Á¿öÁ³´Ù´Â º¸°í°¡ ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ºÐÀïÀÇ ¿µÇâÀ¸·Î º´¿ø, Áø·á¼Ò µî ÀÇ·á½Ã¼³ÀÌ ¼Õ»óµÇ°Å³ª ÆÄ±«µÈ Áö¿ªµµ ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥À» Æ÷ÇÔÇÑ ÇÊ¿äÇÑ ÀÇ·á ¼ºñ½º¸¦ ±¹¹Îµé¿¡°Ô Á¦°øÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù.
The global toxoid vaccine market reached US$ 5,585.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 8,267.2 million by 2030. The market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The presence of key market players holding the majority of the toxoid vaccine market share in the Asia-Pacific region ensures the growth of this region at a high CAGR rate.
For instance, in October 2022, Panacea Biotec, one of India's leading biotechnology companies, received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for the supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).
Moreover, in September 2022, after a successful run with its covid vaccine, the Serum Institute of India focused on designing a vaccine for Diphtheria, Pertussis, and Tetanus (Tdap). The company has presented its phase 2-3 clinical trial data to the Drugs Control General of India (DCGI)'s expert panel seeking permission to manufacture the vaccines. Thus, the data indicate that the Asia-Pacific toxoid market will grow at a high CAGR throughout the forecast period.
The global toxoid vaccine market is the market for vaccines that use toxoids as antigens to create an immune response against specific bacterial diseases, such as tetanus. This type of vaccine is particularly effective at providing protection against tetanus in adults and children aged seven years or older.
The market for toxoid vaccines is expected to grow at a significant rate due to several factors, including the rising prevalence of infectious diseases, increased awareness of the benefits of vaccination, and government-led initiatives aimed at promoting vaccination programs. In addition, ongoing research and development activities and new product launches by major players in the market are expected to further boost the growth of the global toxoid vaccine market.
Government initiatives for toxoid vaccine, such as the Maternal and Neonatal Tetanus Elimination (MNTE) initiative, play a crucial role in driving the global toxoid vaccine market growth. Maternal and Neonatal Tetanus (MNT) is a life-threatening disease that can occur due to unclean deliveries and umbilical cord care practices. The MNTE initiative aims to reduce the number of MNT cases to such low levels that the disease is no longer a major public health problem.
Governments and international organizations, such as the World Health Organization (WHO), have been actively supporting the MNTE initiative by providing funding for immunization programs and public health campaigns. As a result of these initiatives, the global toxoid vaccine market is expected to grow significantly over the forecast period.
The use of the tetanus toxoid vaccine is limited by the occurrence of local reactions such as pain and redness at the site of injection, as well as systemic reactions like fever, fatigue, and muscle pain. Although severe allergic reactions to the vaccine are rare, they can be a concern for a small percentage of people.
Moreover, the incidence of tetanus has declined significantly due to widespread vaccination, resulting in a reduction in demand for the vaccine. The market for tetanus toxoid vaccine is characterized by a dichotomy between the contractual market, which holds a significant share, and the private market.
The toxoid vaccine market has experienced a somewhat mixed impact from the pandemic. While the demand for tetanus toxoid vaccines has remained stable due to their inclusion in routine immunization schedules, the demand for diphtheria toxoid vaccines has declined because of reduced diphtheria incidence in many areas worldwide.
Despite this, the global toxoid vaccine market is projected to continue growing at a steady pace because of the ongoing necessity for vaccination programs to manage infectious diseases. The pandemic's overall impact on the market is predicted to be moderately significant.
The global toxoid vaccine market has not been significantly affected by the ongoing conflict between Russia and Ukraine, as most of the production and distribution is situated outside the conflict zone. However, there have been reports of disruptions in supply chains and difficulties in accessing medical supplies, including vaccines, due to the conflict in the region.
Furthermore, the conflict has resulted in damage or destruction of healthcare facilities, such as hospitals and clinics, in some areas. This has made it challenging for the country to provide necessary healthcare services, including vaccination programs, to the population.
The diphtheria, tetanus, and pertussis (DtaP) segment is expected to hold the highest market share for the global toxoid vaccine market.
The Diphtheria, Tetanus, and Pertussis (DTaP) segment is expected to be the dominant segment in the global toxoid vaccine market, holding 44.2% of the market share over the forecast period. DTaP is a vaccine that helps children under the age of seven develop immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis). The low cost of the vaccine, increasing tetanus cases, and its availability in low-resource economies such as Africa are driving the growth of the DTaP vaccine segment.
In the United States, there are currently seven licensed pediatric DTaP vaccines being used: Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis. The growth of the DTaP vaccine segment during the forecast period is attributed to the increasing prevalence of diphtheria, tetanus, and pertussis, product launches, rising demand for combination vaccines, and high adoption of DTaP vaccines.
The toxoid vaccine market is expected to grow significantly in North America region over the forecast period due to the presence of key market players who hold a major global toxoid market share. The market players have implemented various market strategies such as collaborations, disease launches, and acquisitions to expand their reach and increase their toxoid vaccine market share. It is predicted that North America will dominate the global toxoid vaccine market by acquiring around 2/5th of the market share.
For instance, in June 2022, GSK plc, a global pharmaceutical company, invested a significant amount of over US$1.2 billion in R&D to develop vaccines and medicines to prevent and treat various diseases, including malaria, tuberculosis, HIV, neglected tropical diseases, and diphtheria. All these factors indicate that North America is expected to remain the dominant region in the global toxoid vaccine market.
The major global players in the market include Sanofi S.A., Serum Institute of India Pvt. Ltd., Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, and Abbott.
The global toxoid vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE